Upload
brent-castillo
View
41
Download
0
Embed Size (px)
DESCRIPTION
Medical Management of Claudication: Just Walk it Off!!. Amjad AlMahameed, MD Director, Vascular Medicine Research Associate Staff, Section of Vascular Medicine Department of Cardiovascular Medicine Cleveland Clinic Foundation. Objectives. - PowerPoint PPT Presentation
Citation preview
Amjad AlMahameed, MDDirector, Vascular Medicine Research
Associate Staff, Section of Vascular MedicineDepartment of Cardiovascular Medicine
Cleveland Clinic Foundation
Medical Management of Claudication: Just Walk it Off!!
Objectives
• Recognize the magnitude of PAD as a public health problem
• Review best management strategies
• Reflect on future prospects
Natural History of Intermittent Claudication
Population > 55 y/o
Intermittent Claudication (5%)
Peripheral Vascular Outcomes
Stable Claudication
50-75%
Worsening Claudication
17-25%
Lower Ext Bypass
7%
Major Amputation
4%
Adapted from Weitz JI et al, Circulation 1996, 94:3026 and TASC Working Group J Vasc Surg 2000;31:(suppl 1) S1-296
Cardiovascular Cause75%
Nonfatal CV EventMI/Stroke/other
20%
5 yearMortality
30%
Other Cardiovascular Morbidity/Mortality
Serious, but “not so bad overall”….
PAD Survival* as a Factor of Clinical Severity
*Kaplan-Meier survival curves based on mortality from all causes.*Kaplan-Meier survival curves based on mortality from all causes.††Large-vessel PAD.Large-vessel PAD. Criqui MH et al. Criqui MH et al. N Engl J MedN Engl J Med. 1992;326:381-386.. 1992;326:381-386.
Normal SubjectsNormal Subjects
Asymptomatic LV-PADAsymptomatic LV-PAD††
Symptomatic LV-PADSymptomatic LV-PAD††
Severe Symptomatic LV-PADSevere Symptomatic LV-PAD††
100100
7575
5050
2525
0000 22 44 66 88 1010 1212
Su
rviv
al (
% o
f p
atie
nts
)S
urv
ival
(%
of
pat
ien
ts)
YearYear
The diagnosis of established atherosclerosis in a patient, or identifying that a patient is high risk for atherosclerosis is an:
EVENT
event
event
event
event
Improve Functional Status
Improve Functional Status Save the LimbSave the Limb
Prevent Atherosclerosis
Progression
Prevent Atherosclerosis
Progression
Reduce Cardiac & Cerebrovascular Morbidity/Mortality
Reduce Cardiac & Cerebrovascular Morbidity/Mortality
Decrease the needfor revascularization
Decrease the needfor revascularization
• Improve symptoms
• Improve QOL
• Improve exercise capacity
• Improve symptoms
• Improve QOL
• Improve exercise capacity
Record nonfatalevents (MI/CVA)
Record nonfatalevents (MI/CVA)
Treatment Goals in PADTreatment Goals in PAD
Weitz JI et al. Circulation 1996; 94: 3026
• Systemic Therapy • “Ongoing research”
• Systemic Therapy • “Ongoing research”
Smoking Cessation
• Repeated advice
• Nicotine replacement Rx
• +/- Bupropion
• Behavioral therapy: smoking cessation classes and support groups
• Cessation leads to a reduction in 10 year mortality from 54% to 18%
• Rest pain developed in 0% of quitters compared 16% of continued smokers at seven years
Strategies Benefits
0
5
10
15
20
25
All diabetic patients
Annual event
rate (%)
Insulin-treated
Clopidogrel
Aspirin
12.7%
11.8%
17.7%
15.6%
21.5%
17.7%
* Events=vascular death, MI, stroke, or re-hospitalization for ischemia or bleeding.
Nondiabetic
3821
Events* prevented/
1000 patients
over Aspirin
9
Bhatt DL, et al. Am J Cardiol. 2002;90:625-628.
CAPRIE: Clopidogrel in Diabetes
Statin Therapy
• All pts should be on a statin to achieve a 25% reduction in cholesterol
• Additional treatment may be needed if HDL is low or TG are high
• Remember that HDL and TG (+/- usCRP) are becoming therapeutic targets
• RR=0.81(0.72 to 0.87) for major vascular events (MI, CVA, or revascularization)
• Improved leg functioning, pain-free walking distance, and community-based physical activity independent of cholesterol level
Strategies Benefits of Statin Rx
0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 1.10 1.20
0
10
20
30
40
50
Baseline ABI
Od
ds
of
MI,
Str
oke
, o
r V
ascu
lar
Dea
th
Intensive BP therapy in PAD
Moderate RxIntensive Rx
ACE-I: HOPE Study
0.6 0.8 1.0 1.2
Relative Risk in Ramipril Group
No. of Patients
Incidence of Composite Outcome in Placebo Group
PAD 4051 22.0
No PAD 5246 14.3
HOPE Study Investigators N Eng J Med, 2000, 342:143
Treatment of IC with Exercise Program
• Meta Analysis # 1
• 49 publications, > 600 pts• Statistically significant increase
in:
- Initial claudication distance: 139 meters
- Absolute claudication distance: 176 meters
• Meta analysis # 2:
• 33 publications• Statistically significant increase in:
- Initial claudication distance: 179% from 125.9 +/- 57.3 m to 351.2 +/- 188.7 m
- Absolute claudication distance: 122% (from 325.8 +/- 148.1 m to 723.3 +/- 591.5 m)
Archives of Intern Med 1999, 159: 337 JAMA. 1995 Sep 27;274(12):975-80.
CONCLUSIONS--The optimal exercise program for improving claudication pain distances in patients with peripheral arterial disease uses intermittent walking to near-maximal pain during a program of at least 6 months. Such a program should be part of the standard medical care for patients with intermittent claudication.
Relative Efficacy of Hospital vs. Home-Based Exercise Training (Regensteiner Angiology, 1997, 48:291)
Peak walking time
Pin free walking time
Peak O2 consumption
Functional status evaluated by Walking Impairment Questionnaire (WIQ) and the Medical Outcomes Study SF-20 questionnaire (MOS).
Physical functioning
Walking distance
Improvement in: Unsupervised (N = 10) Supervised (N = 10)
137%
150%
19%
38%
77%
5%
26%
9%
16%
42% (P<0.05)